Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
NATIONAL KIDNEY FOUNDATION

2. Address

Address1
1634 Eye Street, NW
 Address2
​Suite 1050
City
Washington
 State
DC
 Zip Code
20006
 Country
USA

3. Principal place of business (if different than line 2)

City
​New York City
 State
​NY
 Zip Code
​10016
 Country
​USA
4a. Contact Name b. Telephone Number c. E-mail
​Mr.
​TROY ZIMMERMAN
​7034312218
​troyz@kidney.org
5. Senate ID#
​28105-12
7. Client Name Self Check if client is a state or local government or instrumentality
​NATIONAL KIDNEY FOUNDATION
6. House ID#
​306830000
TYPE OF REPORT 8. Year
​2026
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​100,000.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: TROY ZIMMERMAN
 Date
4/16/2026 9:18:07 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

FY 2026 and FY 2027 Appropriations for organ donation and transplantation activities (HRSA).

FY 2026 and FY 2027 Appropriations for CDC, including the Chronic Kidney Disease Initiative.

FY 2026 and FY 2027 Appropriations for kidney research at the National Institute of Diabetes and Digestive and Kidney Diseases.

FY 2026 and FY 2027 Appropriations for Dept. of Defense Congressionally Directed Medical Research Program.

FY 2026 and FY 2027 Appropriations for Indian Health Service.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Natl Institutes of Health (NIH), Health Resources & Services Administration (HRSA), Health & Human Services - Dept of (HHS), Indian Health Service

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Troy
Zimmerman
​
​
Lauren
Drew
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Activities to facilitate organ donation and transplantation, including the Honor our Living Donors Act (H.R. 628, S. 957); the Living Donor Protection Act (S.1552 and H.R. 4583); and legislation to clarify that organ donation surgery qualifies as a serious health condition for FMLA coverage (S. 1552, H.R. 4582).

Implementation of P.L. 118-14, "Securing the U.S. Organ Procurement and Transplantation Network Act."

Support for xenotransplantation.

Comment letter in support for FDA approval of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).

Implementation of the Advancing American Kidney Health Initiative.

Support for telemedicine and telehealth access.

The New Era of Preventing End-Stage Kidney Disease Act (H.R. 1518).

Activities in support of access to affordable, accessible health care, including Affordable Care Act enhanced premium tax credits.





17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), Natl Institutes of Health (NIH)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Troy
Zimmerman
​
​
Lauren
Drew
​
​
Miriam
Godwin
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Initiatives to expand access to home dialysis.

Initiatives to expand eligibility and utilization of the Medicare kidney disease education benefit.

S.1973 and H.R. 4231, "Treat and Reduce Obesity Act," to provide Medicare coverage of anti-obesity medications and obesity treatment.

Support for telemedicine and telehealth access, including the CONNECT for Health Act (S.1261, H.R. 4206) for Medicare beneficiaries.

Comments on the Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program.

Comments on Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model.

Comments on Organ Procurement Organizations (OPO) Conditions for Coverage Revision.

Medicaid eligibility and affordability of coverage under the One Big Beautiful Bill.

Activities to address detection and management of chronic kidney disease.

Support for Medicare Part D Protected Classes.

Implementation of the Advancing American Kidney Health Initiative.




17. House(s) of Congress and Federal agencies Check if None

Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Troy
Zimmerman
​
​
Lauren
Drew
​
​
Miriam
Godwin
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)